<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934685</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingH-01-RT</org_study_id>
    <nct_id>NCT02934685</nct_id>
  </id_info>
  <brief_title>IG-VMAT for Localized Prostate Cancer</brief_title>
  <official_title>A Phase III Randomized Study of Hypofractionated Image-guided Volumetric Modulated Arc Radiotherapy (IG-VMAT) Versus Conventionally Fractionated IG-VMAT in Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if hypofractionated IG-VMAT (70 Gy in 28 fractions over 5.6 weeks) will result
      in disease-free survival (DFS) that is no worse than DFS following conventionally
      fractionated IG-VMAT (80Gy in 40 fractions over 8 weeks) in patients treated for localized
      prostate cancer. Analysis the local progression, disease-specific survival (DFS), freedom
      from biochemical recurrence (FFBR), and overall survival (OS) of two groups. Observe the
      incidence of GI and GU toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical progression free survival</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Number of participants who are free of biochemical relapse after a specified duration of time.Phoenix definition of biochemical failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;acute&quot; adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 4.0</measure>
    <time_frame>From the start of radiation therapy (RT) to first occurrence of worse severity of adverse event within 30 days after the completion of RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to &quot;late&quot; grade 2+ adverse events as assessed by NCI CTCAE v. 4.0</measure>
    <time_frame>From the date of completion of RT to the date of first grade 2 or above adverse event occurring 30 days after the completion of RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>hypofraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 Gy in 28 fractions over 5.6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>convention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80Gy in 40 fractions over 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofraction</intervention_name>
    <description>70 Gy in 28 fractions over 5.6 weeks</description>
    <arm_group_label>hypofraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>convention</intervention_name>
    <description>80Gy in 40 fractions over 8 weeks</description>
    <arm_group_label>convention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50-79

          -  Histologically confirmed prostate adenocarcinoma

          -  Clinical stage T1-3N0M0 according to the AJCC 6th edition

          -  Gleason score must be &gt;5

          -  KPS &gt;70

          -  No radical surgery or cryosurgery for prostate cancer

        Exclusion Criteria:

          -  Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or
             lymphomatous/hematogenous malignancy unless continually disease free for a minimum of
             5 years. (For example, carcinoma in situ of the bladder or oral cavity is permissible)

          -  Evidence of distant metastases

          -  Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer

          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

          -  Previous or concurrent cytotoxic chemotherapy for prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaofeng Li, director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiuzi Zhong</last_name>
    <phone>+86 13810428903</phone>
    <email>drzhongqiuzi@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaofeng Li</last_name>
      <phone>+86 13701062301</phone>
      <email>lgf6243@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Gaofing Li</investigator_full_name>
    <investigator_title>director of radiotherapy department</investigator_title>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

